zerø-frm: Patented Load-Bearing Mycelium Biocomposite (okom wrks labs)

Product · Materials Science

Product · InnDex 22 · Claimed, not yet evidenced · High specification risk

Mycelium biocomposite panels grown in textile molds for load-bearing partition and insulation without internal framing.

zerø-frm is a patented mycelium-based biocomposite (US11866691B2) grown directly in textile molds to create self-supporting interior partition and non-load-bearing insulation panels. It addresses embodied carbon and construction waste in conventional stud-framed partitions and foam insulation by eliminating rigid internal structure and enabling biological growth in place. The material is grown rather than manufactured, reducing processing energy and material throughput.

zerø-frm grows self-supporting interior partition panels inside textile molds using mycelium — the fungal root network — eliminating the stud framing and rigid foam that typically drive embodied carbon in non-structural partitions. The case for the concept is coherent: biological growth in place means no manufacturing energy and no industrial waste, and the patent (US11866691B2) confirms at least one novel claim has been examined. But the record rests on a single 2023 demonstration with no third-party structural, fire, or acoustic test data published, and the risks most relevant to a live project are all critical: the regulatory pathway under IBC and fire codes is undefined, long-term behavior in real HVAC environments is entirely uncharacterized, and moisture sensitivity and biological stability in occupied interiors have not been addressed. The value on offer — closed-loop materials and decentralized production — is genuine if the science matures, but growth cycle time alone (weeks to months) is structurally incompatible with most construction programmes today. A specifier should treat this as a material to track through the research pipeline rather than specify; the honest position is that no basis exists yet for committing it to a building.

Strengths

• Eliminates embodied carbon and manufacturing energy of conventional stud-framed partitions and rigid foam insulation
• Enables decentralized, on-site or near-site material growth, reducing logistics footprint
• Produces panels with integrated insulation and structure in single biological process
• Biodegradable and compostable at end-of-life, closing material loop
• Potentially lower cost per unit if growth cycle and labor scale favorably

Considerations

• Biological material—moisture sensitivity, mold/decay risk, and long-term durability in humid or wet environments not yet characterized (high)
• Growth cycle time (weeks to months) incompatible with fast-track construction schedules (moderate)
• Performance properties (compressive strength, fire rating, acoustic loss) vary with growth conditions; difficult to standardize or QA in field (high)
• Limited to interior, non-load-bearing or lightly loaded use; cannot replace structural framing in most building types (moderate)

Risks

• No published third-party structural test data, fire test, or acoustic performance data; claims rest on single 2023 demonstration (critical)
• No field durability data—long-term behavior in real interior environments (HVAC operation, occupant moisture, thermal cycling) entirely unproven (critical)
• Regulatory pathway (IBC, fire code, ICC approval) undefined; material may not meet building code insulation or fire safety requirements (critical)
• Manufacturability and cost scaling untested; growth conditions, failure rates, and unit economics unknown at production scale (high)
• Biological contamination, pest colonization, or unexpected organism growth in installed panels not addressed (moderate)
• Intellectual property (patent) may restrict licensees' ability to innovate or deploy freely in some geographies (low)

Performance

• Claimed strength vs. prior mycelium composites: 1000% (unverified, no test protocol cited)
• Forming pressure: <15 mmHg (vs. 10–5000 psi in prior art)
• Patent grant: US11866691B2 — January 2024
• Commercial availability: Licensing/partnership inquiry only

Reality check

Patent US11866691B2 confirmed (granted Jan 2024). No peer-reviewed or third-party compressive strength, flexural modulus, or creep-under-load data in public record. Argonne partnership and AXA-XL 2023 demo mentioned in company narrative; neither published results. No documented structural engineers' certification, fire-rating, or moisture/durability testing. Licensing model and no commercial AEC installations with measured performance. Mycelium biocomposites are real; load-bearing claims for this specific product remain unsubstantiated in peer or regulatory domains.

#mycelium_biocomposite #embodied_carbon #interior_partitions #bio_based_insulation #circular_economy

Source